Home>>Signaling Pathways>> Neuroscience>> Neuroendocrinology>>Neuromedin B (trifluoroacetate salt)

Neuromedin B (trifluoroacetate salt) (Synonyms: NMB)

Catalog No.GC44374

Neuromedin B (NMB) is a peptide agonist of the NMB receptor (Ki = 7.4 nM in NCI-H1299 small cell lung cancer cells expressing the human receptor).

Products are for research use only. Not for human use. We do not sell to patients.

Neuromedin B (trifluoroacetate salt) Chemical Structure

Size Price Stock Qty
1mg
$116.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Neuromedin B (NMB) is a peptide agonist of the NMB receptor (Ki = 7.4 nM in NCI-H1299 small cell lung cancer cells expressing the human receptor). It displays similar affinity for frog [Phe13]bombesin receptors (Ki = 11 nM) and lower affinities for human gastrin-releasing peptide receptor and bombesin receptor subtype 3 (Kis = 440 and 4,800 nM, respectively). Intrathecal administration of NMB (0.1-1 nmol) induces dose-dependent itching behavior in mice. NMB (50 μg, s.c.) reduces serum thyroid stimulating hormone (TSH) by 30% in mice indicating a role in pituitary-thyroid axis function. In rodents, NMB is also involved in mediating stress and fear responses, thermoregulation, and can stimulate the contraction of the uterus and gastrointestinal smooth muscle.

Reviews

Review for Neuromedin B (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 36 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Neuromedin B (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.